Abstract:Objective To investigate the safety and clinical efficacy of microparticle transcatheter arterial chemoembolization (mTACE) combined with surgical resection for the treatment of huge hepatocellular carcinoma (hHCC; ≥ 10 cm). Methods A retrospective descriptive study was conducted to gather the clinical data of nine patients with hHCCs treated with mTACE combined with resection in Beijing Tsinghua Changgung Hospital from December 2016 to July 2020. The outcome were as follows: (1) the excellent effect and adverse reactions of mTACE and (2) the efficacy and safety of perioperative resection. Count data were expressed as absolute numbers and percentages. The measurement data of the normal distribution is represented by X ± S, and the measurement data of the skewed distribution are represented by M (range). A paired t-test was used to compare the data of the same patient. p values <0.05 are considered statistically significant. Results (1) Regarding the efficacy and safety of mTACE, all nine hHCCs were treated with mTACE one time. The tumor necrosis rate after particle TACE was (77.6 ± 15.7)% (51.7%–100%); according to the modified response evaluation criteria in solid tumors, the objective response was partial response in eight patients and complete response in one patient. The alpha fetoprotein (AFP) level was abnormal in six cases (>20 ng/mL), of which three cases exceeded the maximum value (>30,000 ng/mL) pre-mTACE. In six patients with abnormal AFP levels, the AFP level decreased in five patients, with a median percentage of 74.5% (35.2%–96.0%). The PIVKA-II level in nine patients was > 40 mAU/mL before mTACE and decreased to varying degrees after mTACE. The median percentage of decline was 76.0% (4.5%–99.8%). The maximum diameter of the tumor decreased from (13.9 ± 1.9) cm (11.0–16.4 cm) to (12.8 ± 1.9) cm (10.4–15.6 cm) (P = 0.001) before surgical resection. Prior to the surgical resection, the tumor volume decreased from (897 ± 244) mL (436–1250 mL) to (750 ± 291) mL (260–1130 mL) (P = 0.001), and the residual liver volume/standard liver volume increased from (42.8 ± 12.8)% (25.8%–61.3%) to (50.2 ± 14.9)% (28.8%–67.4%) (P = 0.008). All patients had embolism syndrome such as fever and abdominal pain in varying degrees, and no serious complications such as liver abscess, liver and kidney failure, or ectopic embolism were noted. (2) For perioperative efficacy and safety, all lesions were successfully resected in (31 ± 11) days (14–48 days) after mTACE. The operation time was (395 ± 79) min (296–540 min), and the amount of intraoperative bleeding was (433 ± 158) mL (200–600 mL). Complications such as biliary fistula, abdominal bleeding, liver and kidney failure, or abdominal infection were not found. The postoperative hospital stay was (13 ± 4) days (9–19 days). No tumor invasion was found at the cutting edge, and hepatic vein invasion was observed in one case. (3) The follow-up ended in November 2021, with a median follow-up of 34 months (16–46 months). Recurrence or distant metastasis occurred in four patients, of which two patients died. The survival times were 18 and 31 months, respectively. The other two patients were followed up for 34 and 41 months. The remaining five patients were followed up for 16–46 months without antitumor treatment or disease progression. Conclusions mTACE combined with tumor resection is feasible for the treatment of patients with hHCC, which needs to be further confirmed by prospective studies.

The Application of Microcatheter in Interventionai Therapy of Hepatic Cell Carcinoma

Assessment of Hepatocellular Carcinoma Undergoing Trans-Catheter Arterial Chemoembolization with Functional Magnetic Resonance Imaging

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

Clinical Application of Microcatheter in Transcatheter Arterial Chemoembolization Therapy for Primary Liver Cancer

Editorial: Interventional Therapy of Hepatocellular Carcinoma

Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma

Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status

Transhepatic Arterial Chemoembolization by Epirubicin Mixed with Microspheres for Hepatocellular Carcinoma

Interventional chemoembolization with hepasphere-loaded microspheres for the treatment of unresec-table hepatocellular carcinoma:preliminary results in 15 cases

Clinical Efficacy of Transcatheter Arterial Chemoembolization Combined With Percutaneous Microwave Coagulation Therapy for Advanced Hepatocellular Carcinoma

Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art

Adjuvant Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Involving Microvascular Invasion.

A new thermosensitive embolic agent used for arterial embolization of primary hepatocellular carcinoma:preliminary clinical trial

Application of transcatheter arterial chemoembolization combined with selective portal vein embolization in two-stage hepatectomy of hepatocellular carcinoma

Chemoembolization of Liver Cancer with Drug-Loading Microsphere 50-100Μm

Advanced Imaging Techniques in the Therapeutic Response of Transarterial Chemoembolization for Hepatocellular Carcinoma

Evaluation on the chemosensitivity of hepatocellular carcinoma during mimetic transcatheter arterial embolization

Super-selective catheterization for “one-way valve occlusion” of the common hepatic artery during transcatheter arterial chemoembolization：discussion on the catheterization skill

The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation Against Hepatocellular Carcinoma

Transcatheter Arterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Exploratory Study of Microparticle Transcatheter Arterial Chemoembolization Combined with Resection for Huge Hepatocellular Carcinoma